Find Clinical Trials

Inclusion Criteria: 1. Women aged ≥18 years and ≤75 years who are newly treated for breast cancer; 2. Pathological examination confirmed HER2 positive (immunohistochemical staining ICH+++ or ICH++ and FISH positive); 3. Patients with invasive breast cancer diagnosed histologically plus imaging as early (T1c-3, N0-1, M0) or locally advanced (T2-3, N2, or N3, M0); 4. ECOG score 0-1; 5. Plan to undergo the final surgical removal of breast cancer, i.e. breast-conserving surgery or total mastectomy, sentinel lymph node (SN) biopsy or axillary lymph node dissection (ALND); 6. If the major organs function normally, the following criteria are met: (1) The standard of blood routine examination should meet: ANC ≥1.5×109/L; PLT ≥90×109/L; Hb ≥90g/L; (2) Biochemical examination should meet the following criteria: TBIL≤ upper limit of normal value (ULN); ALT and AST≤1.5 times the upper limit of normal (ULN); Alkaline phosphatase ≤2.5 times the upper limit of normal (ULN); BUN and Cr≤1.5×ULN and creatinine clearance ≥50 mL/min (Cockcroft-Gault formula); (3) Color Doppler ultrasonography and echocardiography: left ventricular ejection fraction (LVEF≥55%); (4) Fridericia calibrated QT interval (QTcF) for 18-lead ECG \<470 ms; 7. For female patients who are not menopausal or have not been surgically sterilized, they should consent to abstinence or use an effective contraceptive method during treatment and for at least 7 months after the last dose in the study treatment. 8\. Volunteer to join the study and sign the informed consent. Exclusion Criteria: 1. Known allergic history of the drug components of this protocol; 2. Previously received antitumor therapy or radiation therapy for any malignant tumor (except for cured cervical carcinoma in situ and basal cell carcinoma); 3. Has undergone major non-breast cancer related surgery within 4 weeks, or has not fully recovered from such surgery; 4. Stage IV (metastatic) breast cancer patients; 5. Inability to swallow, intestinal obstruction, or other factors affecting the administration and absorption of the drug; 6. Serious heart disease or discomfort that cannot be treated; 7. Suffering from mental illness or psychotropic substance abuse, unable to cooperate; 8. Pregnant or lactating women; 9. Patients with severe liver and kidney function diseases and blood system diseases; 10. Those who were not considered suitable for inclusion by the researchers included: history of drug abuse, history of use of blood products, anticoagulant drugs and immunological drugs within the past year; Poor compliance and refusal to cooperate with treatment

Inclusion Criteria: * Histologically confirmed diagnosis of a solid tumor malignancy harboring AKT1 E17K mutation identified through molecular testing (NGS- or PCR-based) with a Clinical Laboratory Improvement Amendments-certified (or equivalent) diagnostic test. * Unresectable or metastatic disease * Progressed on, intolerant to, or declined prior standard-of-care therapy (including targeted therapy, if applicable) appropriate to tumor type and stage * Evaluable or measurable disease per RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1. * Adequate organ function. Exclusion Criteria: * Prior treatment with PI3K and/or mTOR inhibitors * Patients known to have KRAS, NRAS, HRAS, or BRAF genomic alterations in their tumor * Known condition that prohibits ability to swallow or absorb an oral medication Other inclusion/exclusion criteria may apply.

Inclusion Criteria: * adult patients ; * not taking any antihypertensive medication; * free of any cardiovascular pathology. Exclusion Criteria: * patients who are minors or protected adults ; * patients with BP ≥160/105 mmHg; * history of secondary hypertension; * taking a treatment that may affect blood pressure.

Inclusion Criteria: * University of Colima students linked to the central campus. * Students aged between 18 and 25 years old. * Authorization to participate in the project with a signed informed consent. * Suffer from at least one of the parameters of metabolic disorders or cardiovascular risk (Hyperglycemia, decreased DHL, elevated triglycerides, abdominal obesity or hypertension) following the clinical assessment (Considering the criteria established by the ADA and ATPIII). Exclusion Criteria: * Motor limitations that may hinder the performance of physical exercise. * Pregnancy or lactation. * High Vigorous Physical Activity Level according to the IPA-Q. * To be currently under pharmacological treatment to manage altered metabolic levels. ELIMINATION CRITERIA * Musculoskeletal injuries during the study period. * Unforeseen Medical Events: Unexpected medical situations that could influence study results, such as hospitalizations, serious illnesses, or surgeries. * Non-Compliance with Follow-Up: Subjects failing to meet a minimum of 80% (19 out of 24 sessions) of the stipulated physical conditioning program time. * Initiation of clinical treatment that may affect protocol results, such as medications that reduce alterations. * Participants who voluntarily withdraw from the study.

Inclusion Criteria: 1. At least 18 years old. 2. Sign the informed consent form. 3. Subjects who are willing and able to comply with the requirements of prescribed visits, treatment plans, laboratory examinations and other research procedures. 4. PAH with symptoms was initially diagnosed and belonged to one of the following subgroups: A. Idiopathic pulmonary hypertension (IPAH); B. hereditary pulmonary hypertension (HPAH); C drug or toxin-induced PAH, based on previous exposure to drugs, chemicals or toxins, such as fenfluramine derivatives, other appetite suppressants, toxic rapeseed oil or L- tryptophan. D. PAH is accompanied by: A) connective tissue disease B) Congenital systemic-pulmonary shunt (surgical correction must be performed at least one year before screening, and there is no or no clinically insignificant systemic-pulmonary shunt \[1.0≤ lung-systemic blood flow ratio (QP/QS)≤1.5\]), according to the opinion of the researcher. 5. Received right heart catheterization (RHC) at the time of screening or within 5 years before screening (if RHC is not performed, it will be performed during screening), which is consistent with the diagnosis of PAH and meets all the following criteria: A. mean pulmonary artery pressure (papm) \&gt; 20mmhg (at rest) B pulmonary arteriole wedge pressure (PAWP)≤15 mmHg (if reliable PAWP data cannot be obtained, left ventricular end diastolic pressure \[LVEDP\]≤15 mmHg). C pulmonary vascular resistance (PVR) \&gt; 2.00 wood units (\&gt; 160 dynes/sec/cm5). 6. There are symptoms of WHO/NYHA FC Grade II or III. 7. Stable PAH targeted background oral therapy. Subjects received endothelin receptor antagonist (ERA) and/or phosphodiesterase inhibitor type 5 (PDE5-I) or soluble guanylate cyclase (sGC) agonist. Stability was defined as no change in dose or regimen within 30 days before baseline and during the duration of the study. 8. 6-minute walking distance (6 MWD) ≥ 150m. 9. If the subject is taking concomitant drugs that can affect PAH (for example, calcium channel blockers, digoxin or L- arginine supplements), the dose must be kept stable for at least 30 days before the baseline visit and throughout the study. 10. If there is the possibility of pregnancy, both male and female subjects should agree to use a highly effective contraceptive method during the whole study period (from informed consent to the end of follow-up). Exclusion Criteria: * 1\) Subjects shall not have the following three or more risk factors for left ventricular dysfunction: Body mass index (BMI)≥30 kg/m2 History of systemic hypertension There is any of the following evidence to prove the history of major coronary artery disease: A coronary angiographic evidence of a history of myocardial infarction or percutaneous coronary intervention or coronary artery disease (at least one coronary artery stenosis \&gt; 50%); B. Positive results of exercise provocation test and image evidence; C. previous coronary artery bypass surgery; D. stable angina pectoris; 2) Pulmonary function tests (PFTs) conducted within 180 days before or during the screening showed mild or above lung diseases. Subjects who meet any of the following criteria will be excluded: A. forced expiratory volume in the first second (FEV1)\&lt;60% (expected value); or B total lung volume (TLC) \&lt; 60% of the estimated value. 3) The evidence of thromboembolic disease is confirmed by lung ventilation/perfusion (V/Q) scanning or local standard diagnosis and treatment evaluation at the time of diagnosis or after diagnosis of PAH. 4\) Severe chronic liver disease (i.e. Child-pugh grade C), portal hypertension, cirrhosis or complications of cirrhosis/portal hypertension (e.g., history of varicose bleeding, history of hepatic encephalopathy). 5\) Confirm the active infection of hepatitis B virus (HBV) or hepatitis C virus (HCV). 6\) Subjects whose alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level is more than or equal to 3 times the normal upper limit value (ULN) or whose total bilirubin is more than or equal to 2 times ULN at the time of screening. 7\) Chronic renal insufficiency at screening, which is defined as serum creatinine \&gt; 2.5 mg/dL or requiring dialysis support. 8\) Hemoglobin concentration \&lt; 9 g/dL during screening. 9) diabetes. 10) cardiac function grade IV (NYHA classification) 11) The subject has been treated with IV or SC prostacyclin pathway drugs (for example, epoprostol, triprostinil or iloprost) at any time before baseline (allowed to be used in pulmonary vasodilation test). 12\) The subject has pulmonary vein occlusion disease. 13) Diagnosed and/or treated with malignant tumor within 5 years before screening, but excluding localized non-metastatic basal cell carcinoma or squamous cell carcinoma of the skin, or radical resection of cervical carcinoma in situ. 14\) At the time of screening, there was a history of alcohol or drug abuse within 6 months. 15\) Start the exercise-based cardiopulmonary rehabilitation program within 90 days of the screening period and/or during the study period. 16\) Participated in other interventional clinical studies within 30 days before screening. It is allowed to participate in registered or observational studies at the same time, as long as the subjects meet all other selection criteria and comply with all research process requirements. 17\) Any reason (for example, any past or intermittent diseases) that the respondent thinks may increase the risk of participating in the study or may affect the study analysis and damage the study participation or collaboration, so that the subject cannot participate in the study. 18\) Those who are known to be allergic to Engelgin or any auxiliary materials. 19) According to the researcher\&#39;s judgment, life expectancy is less than 12 months. 20\) Pregnant or lactating women.

Inclusion Criteria: * Patients aged 18 years or older, with a post-stroke period of 03 months or more, based on discharge papers or medical records. * Patients who meet the diagnostic criteria for insomnia according to the DSM-V of the American Psychiatric Association for at least 3 months. Exclusion Criteria: * Patients with insomnia before the stroke. * Patients diagnosed with other sleep disorders such as sleep apnea syndrome, narcolepsy. * Patients diagnosed with neurological diseases or psychiatric disorders such as: Anxiety disorders, autism spectrum disorders, depression, obsessive-compulsive disorder, behavioral disorders affecting sleep before the stroke. * Patients are using antidepressants, psychiatric drugs. * Patients participating in other clinical trials with behavioral, psychological or complementary medical interventions during the study period. * Patients not cooperating during data collection

Inclusion Criteria: * Subjects voluntarily enrolled in this study with good compliance; * Age: 18-75 years old; Eastern Cooperative Oncology Group Performance Status (ECOG PS) score: 0-1; * Pathologically confirmed locally advanced or metastatic breast cancer with low HER2 expression and unresectable: * Defined hormone receptor (HR) status. * Imaging-confirmed disease progression (during or after completion of the most recent treatment); * Have at least one measurable lesion according to RECIST 1.1 criteria; * Good major organ function. Exclusion Criteria: * The presence or current concurrent presence of other malignant tumors within 5 years prior to randomization. ; * Unresolved toxic reactions above Common Terminology Criteria for Adverse Events (CTC AE) grade 1 due to any prior therapy; * Major surgical treatment, incisional biopsy, or significant traumatic injury within 28 days prior to the start of the pre-randomization period; * Prolonged unhealed wounds or fractures; * Previous history of interstitial lung disease/pneumonia requiring steroidal drug intervention; * The presence of moderate to severe pulmonary dysfunction/disease within 3 months prior to randomization; * The presence of an arterial/deep vein thrombotic event within 6 months prior to randomization; * The presence of a medical condition that interferes with intravenous administration, intravenous blood collection, or inability to swallow, chronic diarrhea, intestinal obstruction, or the presence of other factors that interfere with the administration and absorption of medications; * The presence of grade ≥2 myocardial ischemia or myocardial infarction, cardiac arrhythmias (including QT corrected (QTc) ≥450ms (men) and QTc ≥470ms (women)) and grade ≥2 congestive heart failure (New York Heart Association (NYHA) classification); angina pectoris requiring antianginal medication; and clinically significant heart valve disease; * Active or uncontrolled ≥ CTC AE grade 2 infection present within 14 days prior to randomization; * Cirrhosis of the liver, active hepatitis that is not well controlled; * Renal failure requiring hemodialysis or peritoneal dialysis; * History of immunodeficiency, including HIV-positive or other acquired or congenital immunodeficiency diseases, or history of organ transplantation; * Those with routine urinalysis suggestive of urinary protein ≥++ and confirmed 24-hour urine protein quantification \>1.0 g; * Those who have used immunosuppressive or systemic hormone therapy for immunosuppression within 2 weeks prior to randomization; * Those with a history of psychotropic substance abuse that cannot be abstained from or those with psychiatric disorders; * Tumor-related symptoms and treatments: 1. Subjects who have been treated with other antineoplastic agents such as chemotherapy, radical radiotherapy, or immunotherapy within 4 weeks prior to randomization, or who are still within 5 half-lives of the drug (whichever occurs shortest); 2. Treatment with endocrine therapy, molecularly targeted therapy, or a proprietary Chinese medicine with an anti-tumor indication as specified in the National Medical Products Administration (NMPA) approved drug insert within 2 weeks prior to randomization; 3. Presence of carcinomatous lymphadenitis, or uncontrollable pleural effusion, ascites, and pericardial effusion of moderate volume or greater that requires repeated drainage to relieve clinical symptoms, or who have received drainage of plasmapheresis for therapeutic purposes within 2 weeks prior to randomization; 4. Known carcinomatous meningitis or clinically active central nervous system metastases; 5. Severe bone damage resulting from tumor bone metastases; * Those who have received a control chemotherapeutic agent of the investigator's choice during the recurrent metastatic phase or for whom a control chemotherapeutic agent of the investigator's choice is inappropriate for reasons such as intolerance or contraindication to that agent; * Has received prior anti-HER2 therapy; * Who have developed hypersensitivity to humanized monoclonal antibody products; * Those who have developed an allergy to any of the study drugs or any component or excipient in the drugs; * Who have participated in and used another antitumor clinical trial drug within 4 weeks prior to randomization; * Subjects who, in the judgment of the investigator, have a concomitant disease that seriously jeopardizes the safety of the subject or interferes with the completion of the study, or who are deemed to have other reasons for being unsuitable for enrollment.

Inclusion Criteria (subjects must meet all of the following criteria to be included): * 1\) age 18-80 years; * 2\) patients with hypertension (diagnostic criteria: defined as systolic blood pressure ≥ 140 mmHg or diastolic blood pressure ≥ 90 mmHg according to the "Guidelines for the prevention and treatment of hypertension in China in 2023", based on the blood pressure measurement of three times on different days), who are currently taking anti-hypertensive medication and are judged by the research physician to have poor blood pressure control; * 3\) able to use smartphones and WeChat proficiently, and can communicate and upload pictures proficiently; * 4\) able to take care of yourself and communicate normally, and willing to cooperate with the research physician to complete the study and follow-up; * 5\) permanent residents of the city where the center is located; * 6\) voluntarily participate and sign the informed consent form Exclusion Criteria(subjects will be excluded if they meet any of the following criteria): * 1\) patients with advanced disease (such as patients undergoing dialysis or liver failure), or with a life expectancy of less than 2 years as determined by the research physician; * 2\) combined with psychiatric disease, cognitive impairment, communication disorder, or inability to cooperate with the researchers; * 3\) combined with cerebrovascular disease, stroke, severe liver and kidney dysfunction, severe heart failure, cancer and history of organ transplantation, etc.; * 4\) patients who are pregnant, breastfeeding, or planning to conceive in the next 2 years.

Inclusion Criteria: * Clinical diagnosis of primary aldosteronism Exclusion Criteria: * Allergy to drugs in this study * Pregnancy * Severe liver and kidney dysfunction * Mental illness

Inclusion Criteria: * Adults ages 18 to 65 * Current DSM-5 diagnosis of OUD (confirmed during MINI 7 interview) * Current DSM-5 diagnosis of panic disorder with or without agoraphobia (PD/Ag) generalized anxiety disorder, social anxiety disorder, or major depression (confirmed during MINI 7 interview) * Currently in treatment for OUD using MOUD * Access to an internet-enabled smartphone for the duration of the study * Currently residing in the United States * Provision of informed consent Exclusion Criteria: * Current diagnosis of psychosis * Current institutionalization (e.g., jail, hospital) * Self-reported pregnancy * Non-English Speakers

Inclusion Criteria: 1. Patients who are being treated for primary open angle glaucoma using eye drops. 2. Patients with uncontrolled intraocular pressure \&gt;21 mm Hg 3. All recruited patients should have open anterior chamber angles demonstrated on gonioscopy examination. 4. Patients giving consent for operation and follow up Exclusion Criteria: * 1- Pseudophakic patients 2- Advanced glaucoma patients. 3- Patients who are to have trabeculectomy or laser trabeculoplasty. 4- Patients with secondary glaucoma. 5- Patients who are unable to give consent for surgery or follow up. 6- Patients with previous trauma to the eye

Inclusion Criteria: * Uncontrolled treatment resistant hypertension (despite intake of 3 different classes of antihypertensive medications) confirmed by 24-h ambulatory blood pressure according to current guidelines (ESH 2023) (office blood pressure ≥ 140/ and/ or ≥ 90 mmHg and ambulatory blood pressure ≥ 130/ and/or ≥ 80 mmHg * end-stage renal disease on chronic hemodialysis * Stable hemodialysis regime for at least 3 months based on the decision of the treating physician * Patient is adhering to a stable drug regimen without changes for a minimum of 4 weeks. * Individual is ≥ 18 years of age, male and female patients are included. Exclusion Criteria: * Episodes of sustained systolic and/or diastolic hypotension according to 24-h ambulatory blood pressure or dialysis protocols which in the eyes of the treating physician would interfere with a safe renal denervation treatment of the patient * Known hemodynamically or anatomically significant renal artery abnormality or stenosis in either renal artery which in the eyes of the interventionalist would interfere with safe catheter placement * Prior renal denervation procedure * Anatomic or functional solitary kidney, kidney transplantation * Severe atherosclerotic disease or artery calcification preventing the assessment of reliable BP measurements * Endocrine hypertension other than obstructive sleep apnea * Individual has experienced a myocardial infarction, unstable angina pectoris, or a cerebrovascular accident within 3 months of the screening visit * Acute episode of systemic and renal disease requiring uptitration of any immunosuppressive drug regimen within the last 3 months * Subject is pregnant, nursing, or intends to become pregnant * Enrollment in another interventional research protocol. * Any condition that, at the discretion of the investigator, would preclude participation in the study (e.g. non-adherence)

Inclusion Criteria: * 1\) Participants in the study should sign a research informed consent form before starting any research-related procedures; 2) Participants must be between the ages of 16 and 30, regardless of gender; 3) Diagnosed with Major Depressive Disorder (MDD) according to the diagnostic criteria in the DSM-V; 4) Participants must have medical records of their current depressive episode that has lasted for ≥2 years, or recurrent episodes, with a minimum of 4 episodes (with the current episode lasting at least 1 year); 5) Have previously failed at least 3 courses of adequate antidepressant therapy, using 2 or more different classes of antidepressants; and have refused, been unable to tolerate, or found electroconvulsive therapy (ECT) to be ineffective; 6) Participants must have a HAMD-17 score of ≥20 or a MADRS score of ≥25; 7) Participants must be able to communicate effectively, and the participant and their legal guardian must sign a written informed consent form. Exclusion Criteria: * 1\) Participants with bipolar disorder, schizoaffective disorder, schizophrenia, or other psychotic disorders; 2) Severe personality disorders; 3) Severe physical diseases or organic brain diseases; 4) Participants with alcohol or substance abuse and dependence diagnosed within 1 year prior to screening according to DSM-IV criteria; 5) Participants with surgical contraindications, such as significant comorbid medical conditions or inability to discontinue anticoagulation medications; 6) Structural imaging abnormalities evident on MRI performed within 1 year prior to screening; 7) MRI contraindications (excluding DBS implantation or the device itself); 8) Pregnant or breastfeeding; 9) Participants who are enrolled in another study unrelated to the current study; 10) Any condition that may currently or potentially endanger the participant's safety or preclude their successful participation in the study (family support, medical, psychological, social, or geographic factors).

Inclusion Criteria: * Adolescents enrolled in the selected secondary schools will be eligible. * Parents of adolescents enrolled in the selected schools will be eligible * Teachers and school staff: All teachers and school staff working in the selected schools will be eligible. * Participants can be of any gender. * Teachers and school staff will have to be older than 18 years. Exclusion Criteria: • Apart from not signing the informed consent, no exclusion criteria will be applied.

Inclusion Criteria: IIIC stage breast cancer patients Exclusion Criteria: Other stages breast cancer patients

Inclusion Criteria: * 1\. must have a histologically or cytologically confirmed diagnosis of breast cancer with evidence of locally advanced disease unsuitable for excision or radical radiotherapy, or evidence of metastatic disease unsuitable for radical treatment. * 2\. female ≥ 18 years of age * 3\. female subjects must be postmenopausal (meeting any of the following criteria is sufficient) a) Has undergone oophorectomy. b) Age ≥ 60 years. c) 40 years old \< age ≤ 60 years old with 1 year of menopause. d) Age \<60 years and receiving ovarian suppression therapy. * 4\. ER-positive and HER2-negative status and ESR1-mutation positive must be confirmed. * 5\. must have progressed on at least one line of endocrine therapy prior to enrollment, including monotherapy or combination therapy. * 6\. have normal organ function (as assessed by the investigator). Exclusion Criteria: * 1\. women who are pregnant or breastfeeding * 2\. known difficulties in tolerating oral medications, or conditions that interfere with the absorption of oral medications or allergies to medications and their excitements * 3\. other conditions that make enrollment in the study unsuitable, at the discretion of the investigator

Inclusion Criteria: * Age 18+ (looking for older adults) * Native Hawaiian resident in a participating homestead * Overweight or obese (BMI ≥ 25 kg/m\^2) * Prior diagnosis of type 2 diabetes or pre-diabetes, hypertension, and/or dyslipidemia (LDL cholesterol ≥ 130 mg/dL) * Capable of 150 minutes of moderate physical activity (e.g., brisk walking) per week * Willing and able to participate in all aspects of the individual and household-level intervention * Fluent in written and spoken English Exclusion Criteria: * No children * Pregnancy * Serious illness such as cancer or chronic pain that may contraindicate full participation

Inclusion Criteria: * 1\. must have a histologically or cytologically confirmed diagnosis of breast cancer with evidence of locally advanced disease unsuitable for excision or radical radiotherapy, or evidence of metastatic disease unsuitable for radical treatment. * 2\. female ≥ 18 years of age * 3\. female subjects must be postmenopausal (meeting any of the following criteria is sufficient) a) Has undergone oophorectomy. b) Age ≥ 60 years. c) 40 years old \< age ≤ 60 years old with 1 year of menopause. d) Age \<60 years and receiving ovarian suppression therapy. * 4\. ER-positive and HER2-negative status and ESR1-mutation positive must be confirmed. * 5\. must have progressed on at least one line of endocrine therapy prior to enrollment, including monotherapy or combination therapy. * 6\. have normal organ function (as assessed by the investigator). Exclusion Criteria: * 1\. women who are pregnant or breastfeeding * 2\. known difficulties in tolerating oral medications, or conditions that interfere with the absorption of oral medications or allergies to medications and their excitements * 3\. other conditions that make enrollment in the study unsuitable, at the discretion of the investigator

Inclusion Criteria: * male, female or non-binary * age ≥ 18 years * diagnosis of T2DM secured via submission of a medical certificate attesting to the presence of at least one of the following ICD-10-GM diagnoses of T2DM: E11.20, E11.30, E11.40, E11.50, E11.60, E11.72, E11.74, E11.80, E11.90 * elevated levels of diabetes-specific emotional distress: cut-off ≥ 33 on the PAID-20 * access to CGM-compatible smartphone * consent to participate * sufficient knowledge of the German language Exclusion Criteria: * diagnosis of type 1 diabetes mellitus (T1DM) * change in medication (type, frequency of use or dosage) within 4 weeks before the baseline visit or planned within the subsequent 6 months * recent or planned bariatric operation within 4 weeks before the baseline visit or within the subsequent 6 months * change in psychotherapeutic treatment within 4 weeks before the baseline visit or planned within the subsequent 6 months * current use of continuous glucose monitoring (CGM) as part of one's diabetes treatment * experiencing problems with the CGM sensor or insufficient CGM data quality at baseline (T0) (i.e., wearing the CGM sensor on less than 6 of 7 days, providing less than a minimum of 96 hours of glucose values, providing less than 24 hours overnight CGM data)

Inclusion Criteria: * Age: 16 years to 90 years * Histologically diagnosed as primary/relapsed/metastasized Breast Cancer * Expected life span more than 3 months * Karnofsky≥60% or ECOG score 0-2 * Test subjects have failed standard treatment regimens, or there are no standard treatment regimens available. * Test subjects must have tumor regions eligible for biopsy or resection, or malignant body fluid where TILs can be isolated * At least 1 evaluable tumor lesion * Hematology and Chemistry（within 7 days prior to enrollment）: * Absolute count of white blood cells≥2.5×10\^9/L * Absolute count of neutropils≥1.5×10\^9/L * Absolute count of lymphocytes ≥0.7×109/L * Platelet count≥100×10\^9 * hemoglobin≥90 g/L * Activated partial thromboplastin time (APTT) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days) * International normalized ratio (INR) ≤1.5xULN (Unless received anticoagulant therapy within the previous 3 days) * Serum creatinine ≤1.5mg/dL(or ≤132.6μmol/L), or clearance rate≥50mL/min * Serum ALT/AST ≤3×ULN(subjects with liver metastasis ≤3×ULN) * Totol bilirubin≤1.5×ULN * No absolute or relative contraindications to operation or biopsy * Test subjects with child-bearing potential must be willing to practice approved highly effective methods of contraception at the time of informed consent and continue within 1 year after the completion of lymphodepletion * Any malignant tumor-targeting therapies, including radiotherapy, chemotherapy, and biologics must cease 28 days before obtaining TILs * Be able to understand and sign the informed consent document; * Be able to stick to follow-up visit plan and other requirements in the agreement. Exclusion Criteria: * Need glucocorticoid treatment, and daily dose of Prednisone greater than 15mg (or equivalent doses of hormones) or outoimmune diseases requiring immunomodulatory treatment * Forced expiratory volume in one second (FEV1) less than 2L, diffusing capacity of the lung for carbon monoxide (DLCO) (calibrated) less than 40% * Significant cardiovascular anomalies according to any of the following definitions: * New York Heart Association (NYHA) Grade III or IV congestive heart failure, clinically significant * Low blood pressure, uncontrollable symptomatic coronary artery diseases, or ejection fraction less than 35%; Severe cardiac rhythm and conduction anomaly, such as ventricular arrhythmia requiring clinical intervention, second-third degree atrioventricular conductive block, etc. * Human immunodeficiency virus (HIV) infection or anti-HIV antibody positive, active HBV or HCV infection (HBsAg positive and/or anti-HCV positive), syphilis infection or Treponema pallidum antibody positive. * Severe physical or mental diseases; * Have a systemic active infection requiring treatment, or have positive blood cultures(or imaging evidence of infection). * Having been treated within a month or being treated now with other medicines, or other biologic therapy, chemo-or radiotherapy. * History of allergy to chemical compounds consisting of chemical and biological substances resembling cell therapy. * Having received immunotherapy and developed an irAE level greater than Level 3. * Previous anti-tumor treatment AE did not return to CTCAE5.0 version grade 1 or below (toxicity considered by the investigator as non-safety concerns like alopecia excluded). * Females in pregnancy or lactation. History of organ transplantation, allogeneic stem cell transplantation, and renal replacement therapy. * Researchers consider the test subject as having a history of other severe systemic diseases, or other reasons inappropriate for the clinical study.